Target Details
| UniProt AC | P42345 |
|---|---|
| Gene Symbol | MTOR |
| Protein Name | Serine/threonine-protein kinase mTOR |
| Organism | Homo sapiens |
| Entry Name | |
| Organism Category | Human |
| Pfam Domains | PF02259 (FAT) PF02260 (FATC) PF08771 (FRB_dom) PF23593 (HEAT_ATR) PF11865 (mTOR_dom) PF00454 (PI3_PI4_kinase) |
Summary
- Multi-target molecules 2,517
- Clinical molecules 193
- Avg pChEMBL 7.75
KEGG Pathways (53)
- AMPK signaling pathway
- Acute myeloid leukemia
- Adipocytokine signaling pathway
- Alzheimer disease
- Amyotrophic lateral sclerosis
- Apelin signaling pathway
- Autophagy - animal
- Autophagy - other
- Breast cancer
- Cellular senescence
- Central carbon metabolism in cancer
- Chemical carcinogenesis - receptor activation
- Choline metabolism in cancer
- Colorectal cancer
- Diabetic cardiomyopathy
- EGFR tyrosine kinase inhibitor resistance
- Endocrine resistance
- ErbB signaling pathway
- Gastric cancer
- Glioma
- Growth hormone synthesis, secretion and action
- HIF-1 signaling pathway
- Hepatocellular carcinoma
- Herpes simplex virus 1 infection
- Human cytomegalovirus infection
- Human immunodeficiency virus 1 infection
- Human papillomavirus infection
- Huntington disease
- Insulin resistance
- Insulin signaling pathway
- Integrin signaling
- JAK-STAT signaling pathway
- Kaposi sarcoma-associated herpesvirus infection
- Longevity regulating pathway
- Longevity regulating pathway - multiple species
- Lysosome biogenesis
- MicroRNAs in cancer
- Neutrophil extracellular trap formation
- PD-L1 expression and PD-1 checkpoint pathway in cancer
- PI3K-Akt signaling pathway
- Pancreatic cancer
- Pathways in cancer
- Pathways of neurodegeneration - multiple diseases
- Phospholipase D signaling pathway
- Prostate cancer
- Proteoglycans in cancer
- Shigellosis
- Spinocerebellar ataxia
- Th17 cell differentiation
- Thermogenesis
- Thyroid hormone signaling pathway
- Type II diabetes mellitus
- mTOR signaling pathway
Associated Diseases (2)
Active Molecules (2,517)
| InChIKey | pChEMBL | Type | Targets | Clinical | |
|---|---|---|---|---|---|
IONVFRIQYMBCJN
|
10.4 | IC50 | 3 | — | |
OSMZXIBKLUZNAF
|
10.2 | IC50 | 2 | — | |
DLIGFKRUAOAIBA
|
10.1 | IC50 | 3 | — | |
ATLHTKSZGMIXLX
|
10.0 | IC50 | 2 | — | |
AUXKCHHCFDLRBV
|
10.0 | IC50 | 2 | — | |
CKBQNLZZMPQJMA
|
10.0 | IC50 | 2 | — | |
HNNBGLRKAYUYCE
|
10.0 | IC50 | 2 | — | |
JYJRBELNIAMUFK
|
10.0 | IC50 | 2 | — | |
PWOJHTAZPQKPPN
|
10.0 | IC50 | 4 | — | |
ATPLVZHZSJDMFY
|
10.0 | IC50 | 2 | — | |
SRIMYUDGKMDALL
|
9.9 | Ki | 2 | — | |
HGTXRLXWYACZEB
|
9.9 | IC50 | 2 | — | |
QAQUVBOSSUCOMU
|
9.9 | IC50 | 2 | — | |
QYCBARGBDSITAT
|
9.9 | IC50 | 2 | — | |
DTUJUZUXGBVDHP
|
9.8 | IC50 | 2 | — | |
VBYNNESGSHUXND
|
9.8 | IC50 | 2 | — | |
NGJVDJJMXFCUOB
|
9.8 | IC50 | 2 | — | |
COKADSMBFNSRTG
|
9.7 | IC50 | 2 | — | |
QYRNAZNHSSTFBK
|
9.7 | IC50 | 2 | — | |
IBRCKRMEQSGILN
|
9.7 | IC50 | 2 | — | |
LGSOBLATILGMLK
|
9.7 | IC50 | 2 | — | |
LWXZJXVFHWPDBG
|
9.7 | IC50 | 3 | — | |
ODSKIIXTBSXLGG
|
9.7 | IC50 | 2 | — | |
QOMUOLVLUYYLAR
|
9.7 | IC50 | 2 | — | |
QWUNRYMMAGVRMS
|
9.7 | IC50 | 2 | — | |
SXCSSRFIAVDRJT
|
9.7 | IC50 | 2 | — | |
BYCVGFYVNZPDJW
|
9.7 | Ki | 2 | — | |
QSWDLPGTHDVTAS
|
9.7 | IC50 | 2 | — | |
ZUUDJPWGLNVXOA
|
9.7 | IC50 | 2 | — | |
KHMMMZFXKIACGP
|
9.6 | IC50 | 3 | — | |
LQBQQAXIISEIGM
|
9.6 | IC50 | 2 | — | |
ZQVPQBARVVEJLR
|
9.6 | Ki | 2 | — | |
FQDRPOULRUASJV
|
9.6 | Ki | 2 | — | |
GUXXEUUYCAYESJ
|
9.6 | IC50 | 11 | — | |
KNCBLPFPBXCIEU
|
9.6 | IC50 | 3 | — | |
OWVQWEHJNRKTSY
|
9.6 | IC50 | 2 | — | |
VASVVUWIZPDIFI
|
9.6 | IC50 | 2 | — | |
JIYAJGRQHOMQIB
|
9.6 | IC50 | 2 | — | |
OVZXUGCOPDRTLO
|
9.6 | IC50 | 3 | — | |
WTZBKPPOAGVOMK
|
9.6 | IC50 | 2 | — | |
KQUCUYUNGWREBC
|
9.6 | IC50 | 2 | — | |
CHLJLODIXLIFHL
|
9.6 | IC50 | 3 | — | |
JMOLMCBABVAYTF
|
9.6 | IC50 | 2 | — | |
KPXVSFMQOAWOEC
|
9.6 | IC50 | 2 | — | |
DAAVZNAOKHUQJR
|
9.5 | IC50 | 2 | — | |
DDZSBINJAGOFDK
|
9.5 | IC50 | 3 | — | |
DHWMEOLHCVFNTG
|
9.5 | IC50 | 2 | — | |
IKYYAFMKEGKZGC
|
9.5 | IC50 | 2 | — | |
ADCADUHNSKXDGZ
|
9.5 | IC50 | 2 | — | |
BTYNBZGKZGRDNC
|
9.5 | IC50 | 2 | — |